BioWorld MedTech

March 7, 2011

High risk, narrow markets stunting growth for MDx

VIENNA – The bubble of hype surrounding molecular diagnostics (MDx) has burst, leaving Fabian Kiessling, MD, a lone voice still preaching its promise at this radiology congress. (Medical Device Daily) Read More

FDA clears IVD assays from Wako for liver cancer risk

Washington roundup: Medtronic needles CMS into reopening MRI/EP coverage

When a deal value deferred by milestones is still a good deal

Report from Europe: Medtronic launches Achieve mapping catheter in Europe

HIT roundup: TotalQuality certified as EHR technology reporting module

Court Report: Bovie settles patent suit with Medtronic, Salient Surgical

Patent watch: Biolase wins new U.S. patent for treating eye conditions

Med-Tech Notes

Product Briefs

FDA issues a Class I recall of Cook catheter component

Agreements/contracts: ScandiDos Delta4PT to use Varian's RapidArc technology

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 15, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

Blood glucose chart and monitor, stethoscope, injector pen

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes

BioWorld

Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2...